VEGF Function in B-CLL

VEGF 在 B-CLL 中的功能

• 批准号: 7667268
• 负责人: Neil E Kay
• 金额: $ 26.88万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-10 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7667268
• 关键词: Address; Aging; American; Angiogenic Factor; Angiogenic Proteins; Apoptosis; Apoptotic; Avastin; B lymphoid malignancy; B-Lymphocytes; Binding; Biology; Cell Culture Techniques; Cell Death; Cell Nucleus; Cells; Chronic Lymphocytic Leukemia; Clinical; Clinical Trials; Defect; Degradation Pathway; Disease; Disease Management; Disease Progression; Doctor of Medicine; Down-Regulation; Drug resistance; Elements; Event; Experimental Designs; Exposure to; Fibronectins; Goals; Hydroxylation; Hypoxia; In Vitro; Individual; Indolent; Interruption; Marrow; Mediator of activation protein; Membrane; Messenger RNA; Molecular; Monoclonal Antibodies; Neuropilin-1; Outcome; Pathway interactions; Patients; Pattern; Pharmaceutical Preparations; Phase II Clinical Trials; Plasma; Play; Population; Process; Production; Proteins; Reagent; Refractory; Relapse; Relative (related person); Research Personnel; Resistance; Risk; Role; STAT3 gene; Signal Transduction; Signaling Molecule; Small Interfering RNA; Staging; Stratification; Therapeutic; Thrombospondin 1; Tyrosine Kinase Inhibitor; Vascular Endothelial Growth Factor Receptor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; ZAP-70 Gene; angiogenesis; autocrine; base; bevacizumab; cell killing; cohort; design; in vivo; inhibitor/antagonist; insight; killings; neovascularization; novel; overexpression; programs; receptor; research study; response; transcription factor; tumor progression

DESCRIPTION (provided by applicant): B-CLL represents a very common B cell malignancy without a curative approach. Given the aging of the North American population and the continued absence of a means to eradicate this disease, the management remains very difficult. Thus, novel insights into the biology of B-CLL are essential if we are to make progress. Angiogenesis in B-CLL is increasingly implicated as relevant to the biology of the disease process. For example we have found that the neovascularization found in CLL marrow increases as the disease stage progresses and that a VEGF based autocrine pathway induces increases in CLL B cell leukemic apoptotic resistance. This latter aspect we feel is crucial as the biologic hallmark of CLL B cells are their resistance to cell death or apoptosis. The CLL B cell elaborates VEGF that is able to bind to CLL B cell VEGFR-1 and VEGF-R2 type receptors with subsequent enhancement of the leukemic CLL B cell apoptosis resistance. We have gained some insight into the relevant downstream signaling molecules in particular that STAT3 activation and translocation into the CLL nucleus occurs with exposure of CLL B cells to VEGF. In addition, we have found that agents which interrupt the VEGF autocrine pathway, such as Bevacizumab (Avastin) can result in increased CLL B cell killing. In addition we now know that HIF1a a key transcription factor for VEGF is consistently overexpressed in CLL B cells. We have yet to understand the relative importance of each VEGF receptor in signaling and why other mediator molecules such as HIF1a are elevated in CLL B cells. We propose that with further analysis of the role of the VEGF membrane receptors in signaling of CLL B cells, understanding why HIF1a is elevated in these cells and determining what signaling events are critical to CLL B cell apoptosis resistance that we will have important biologic information that will allow us to exploit these findings for therapeutic purposes. Finally, if the administration of Bevacizumab in a clinical trial setting can result in reduction in leukemic CLL B cell levels of relapsed/refractory B-CLL patients and/or generate clinical responses (see appendix 1 for clinical trial) we will validate that a VEGF based pathway is highly relevant to B-CLL progression. Our specific aims in this proposal are: 1) Evaluate the impact and mechanism by which the angiogenic factor, VEGF when secreted by CLL B cells, alters CLL B cell apoptosis and drug resistance. 2) To determine the mechanism for increased production of VEGF in B-CLL B cells cultured under normoxic and hypoxic conditions. 3) Does the VEGF/VEGF-R pathway(s) found in CLL B cells correlate with either clinical and/or critical biologic parameters in B-CLL?

描述(申请人提供)：B-CLL是一种非常常见的B细胞恶性肿瘤，没有治疗方法。鉴于北美人口老龄化，以及继续缺乏根除这种疾病的手段，管理仍然非常困难。因此，如果我们要取得进展，对B-CLL生物学的新见解是必不可少的。B-CLL中的血管生成越来越多地被认为与疾病过程的生物学相关。例如，我们发现在CLL骨髓中发现的新生血管随着疾病阶段的进展而增加，并且基于血管内皮生长因子的自分泌途径诱导CLL B细胞对凋亡的抵抗力增加。我们认为后一方面是至关重要的，因为CLL B细胞的生物学标志是它们对细胞死亡或凋亡的抵抗力。CLL B细胞分泌能够与CLL B细胞VEGFR-1和VEGF-R2受体结合的血管内皮生长因子，从而增强白血病CLL B细胞的抗凋亡能力。我们已经对相关的下游信号分子有了一些深入的了解，特别是当CLL B细胞暴露于血管内皮生长因子时，STAT3的激活和转位到CLL核发生。此外，我们还发现，阻断血管内皮生长因子自分泌途径的药物，如贝伐单抗(阿瓦斯丁)，可以导致CLL B细胞杀伤增加。此外，我们现在知道，HIF1a是血管内皮生长因子的关键转录因子，在CLL B细胞中持续过表达。我们还不知道每个血管内皮生长因子受体在信号传递中的相对重要性，以及为什么其他介质分子，如HIF1a，在CLL B细胞中升高。我们认为，随着进一步分析血管内皮生长因子膜受体在CLL B细胞信号转导中的作用，了解HIF1a在这些细胞中升高的原因，并确定哪些信号事件对CLL B细胞的凋亡抵抗至关重要，我们将拥有重要的生物学信息，使我们能够利用这些发现进行治疗。最后，如果在临床试验中给予贝伐单抗可以降低复发/难治性B-CLL患者的白血病CLL B细胞水平和/或产生临床反应(临床试验见附录1)，我们将验证基于血管内皮生长因子的途径与B-CLL进展高度相关。本研究的目的是：1)评价血管生成因子--血管内皮生长因子在CLL-B细胞分泌时对CLL-B细胞凋亡和耐药性的影响及其机制。2)探讨常氧和低氧条件下培养的B-CLL B细胞分泌血管内皮生长因子的机制。3)在B细胞中发现的血管内皮生长因子/血管内皮生长因子受体通路(S)是否与B-CLL的临床和/或关键生物学参数相关？